This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Express Scripts-Medco Deal: Impact on Walgreen Stock

Stocks in this article: WAG

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK ( Trefis) -- Walgreen (WAG) announced its second-quarter results last week. The earnings beat analyst expectations even though the number of prescriptions filled at comparable stores fell by 8% to 9% as a result of the drug retailer walking out of Express Scripts network this year. What is generating more curiosity is the future of Walgreen's business with Medco now that the FTC has approved the Express Scripts-Medco deal.

The company's management indicated in its latest earnings call that it hopes to maintain its relationship and contracts with Medco. Others speculate that Walgreen may hammer out a fresh deal with Express Scripts soon. This certainly bodes well for WAG stock which currently trades at $35, and has lost almost a quarter of its value since its impasse with Express Scripts in June 2011. Walgreen competes with CVS Caremark (CVS) and Rite Aid (RAD).

View our analysis for Walgreen .

Walgreen and Express Scripts parted ways last year after failing to renew contract worth $5 billion over disagreement on reimbursement rates. As the FTC has approved the merger between Express Scripts and Medco Health Solutions, there are concerns about the implications for Walgreen and the future of its prescription business from Medco (Walgreen filled 125 million prescriptions for Medco clients in 2011). There were also talks of Walgreen considering buying out Rite Aid.

The recent buzz is that Walgreen could try to enter a new contract with Express Scripts as the management appeared positive about doing business with Medco. In fact, UBS expects the deal as soon as April or May and has even raised its price target for Walgreen to $39. This would certainly be in the interests of both Walgreen and Express-Medco.

We currently value Walgreen with a $35 Trefis price estimate of its stock, which is 3% ahead of the current market price.

Click here to find out how a company's products impact its stock price at Trefis

Like our charts? Embed them in your own posts using the Trefis Wordpress Plugin.

This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs